Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin. NLM AIDSLINE Important note: Information in this article was accurate in 1998. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Liposomal doxorubicin in pulmonary Kaposi's sarcoma: improved survival as compared to patients without liposomal doxorubicin.

Eur J Med Res. 1998 Feb 21;3(1-2):13-9. Unique Identifier : AIDSLINE MED/98174147
Grunaug M; Bogner JR; Loch O; Goebel FD; Medizinische Poliklinik, Ludwig-Maximilians-University, Munich,; Germany.

Abstract: OBJECTIVE: Pulmonary Kaposi's sarcoma (KS) in HIV-infected patients is characterised by a poor prognosis with a mean survival time of 2 to 6 months. Our goal was to evaluate survival in patients with pulmonary KS treated with Stealth liposomal doxorubicin (SL-DOX) and to compare it with patients without SL-DOX therapy. PATIENTS AND THERAPY: 29 AIDS patients with confirmed pulmonary Kaposi's sarcoma were studied. Group 1 (n = 20): Patients treated with SL-DOX. Group 2 (n = 9): 4 patients who received bleomycin and vinblastine or vincristine and 5 patients without chemotherapy. RESULTS: Survival analysis by Kaplan-Meier plot showed a significant benefit for patients with SL-DOX treatment. Mean survival times were 11.8 +/- 1.78 months group 1: range 1-28) versus 4.4 +/- 1.68 months (group 2; range 1-17). Average CD4 levels did not differ significantly at diagnosis of pulmonary Kaposi's sarcoma. Clinical response included improvement of general health, particularly cough and dyspnea, of arterial pO2 and radiographic KS pattern in the lung. CONCLUSION: Our analysis suggests a clear survival and quality of life benefit for patients with pulmonary Kaposi's sarcoma on liposomal doxorubicin.
Keywords: *Doxorubicin/ADMINISTRATION & DOSAGE *Lung Neoplasms/DRUG THERAPY *Sarcoma, Kaposi/DRUG THERAPY

KWDdoxorubicin/administration&dosageKWDlungneoplasms/drugtherapyKWDsarcoma,kaposi/drugtherapy
980730
M9871337

Copyright © 1998 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .